Retatrutide

CAS #: 2381089-83-2

Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight: approx. 4,731.33 g/mol

Retatrutide is a triple agonist that targets three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. By activating all three pathways, retatrutide exerts powerful effects on blood sugar regulation, appetite suppression, energy expenditure, and fat metabolism. Unlike dual agonists such as tirzepatide, retatrutide adds glucagon receptor activity, which increases energy expenditure and fat oxidation — contributing to more dramatic weight loss effects.

• Superior Weight Loss: In clinical trials, retatrutide has demonstrated weight loss exceeding 24% of total body weight at higher doses — surpassing both semaglutide and tirzepatide.
• Comprehensive Metabolic Control: Triple receptor activation improves HbA1c, fasting glucose, and cardiometabolic markers beyond GLP-1–only therapies.
• Increased Energy Expenditure: Glucagon receptor activation increases calorie burn and fat oxidation, making it metabolically distinct from GLP-1/GIP-only agents.
• Enhanced Fat Reduction: Demonstrates significant reductions in visceral adipose tissue and liver fat.
• Potent Appetite Suppression: Combined GLP-1 and GIP signaling reduces hunger while glucagon balances metabolic rate, supporting sustained weight loss.

Because of its triple-mechanism profile, retatrutide is considered one of the most metabolically aggressive incretin-based therapies currently in development.

*Shipping only available in the continental U.S.*

All products on this site are for research and development use only.